Sonoma Pharmaceuticals, Inc. (SNOA) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
30Y Low34.3·High34.3
P/B Ratio
↓
0.34
↓-83% vs avg
5yr avg: 1.98
30Y Low0.5·High126.3
ROE
↑
-65.5%
↓+4% vs avg
5yr avg: -68.0%
30Y Low-484%·High59%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SNOA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Sonoma Pharmaceuticals, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2M | $3M | $3M | $7M | $21M | $30M | $14M | $16M | $33M | $61M | $74M |
| Enterprise Value | $-2992264 | $-2351210 | $506970 | $4M | $15M | $28M | $12M | $12M | $24M | $44M | $67M |
| P/E Ratio → | -0.43 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.15 | 0.19 | 0.24 | 0.50 | 1.68 | 1.59 | 0.81 | 0.82 | 2.00 | 4.72 | 7.91 |
| P/B Ratio | 0.34 | 0.62 | 0.49 | 0.83 | 2.45 | 5.53 | 2.57 | 1.49 | 2.18 | 2.83 | 7.31 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SNOA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.16 | 0.04 | 0.28 | 1.21 | 1.51 | 0.65 | 0.65 | 1.43 | 3.39 | 7.12 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SNOA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Sonoma Pharmaceuticals, Inc. earns an operating margin of -26.0%. Operating margins have expanded from -34.4% to -26.0% over the past 3 years, signaling improving operational efficiency. A negative ROE of -65.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.2% | 38.2% | 37.3% | 33.7% | 31.6% | 35.2% | 45.3% | 46.8% | 43.9% | 44.2% | 28.3% |
| Operating Margin | -26.0% | -26.0% | -36.9% | -34.4% | -46.6% | -18.5% | -41.2% | -59.3% | -85.2% | -101.2% | -157.0% |
| Net Profit Margin | -24.2% | -24.2% | -38.0% | -38.8% | -40.3% | -21.2% | -18.5% | -62.2% | -86.0% | 72.3% | -108.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -65.5% | -65.5% | -68.5% | -61.8% | -72.3% | -71.9% | -41.1% | -91.4% | -78.0% | 58.8% | -91.6% |
| ROA | -24.3% | -24.3% | -31.2% | -29.4% | -30.1% | -26.7% | -22.8% | -70.1% | -64.2% | 47.2% | -70.4% |
| ROIC | -188.1% | -188.1% | -81.8% | -89.3% | -136.1% | -78.4% | -110.2% | -129.0% | -208.8% | -271.6% | -251.1% |
| ROCE | -36.0% | -36.0% | -39.9% | -35.8% | -49.2% | -33.3% | -71.4% | -84.0% | -74.5% | -80.0% | -129.5% |
SNOA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $305000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.10 | 0.11 | 0.16 | 0.50 | 0.15 | 0.05 | 0.04 | 0.02 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.15 | -0.41 | -0.37 | -0.69 | -0.29 | -0.51 | -0.31 | -0.62 | -0.80 | -0.73 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -588.70 | -287.42 | -461.88 | -341.15 | -354.73 | -4324.67 | -4904.67 |
Net cash position: cash ($5M) exceeds total debt ($305000)
SNOA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Sonoma Pharmaceuticals, Inc.'s current ratio of 3.09x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.38x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 3.71x to 3.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 3.37 | 3.71 | 2.82 | 3.18 | 2.62 | 3.48 | 4.98 | 6.89 | 3.63 |
| Quick Ratio | 2.38 | 2.38 | 2.64 | 2.94 | 2.37 | 2.56 | 2.16 | 2.53 | 4.11 | 6.21 | 3.17 |
| Cash Ratio | 1.31 | 1.31 | 0.84 | 1.03 | 1.27 | 1.03 | 0.78 | 1.03 | 3.09 | 5.31 | 2.10 |
| Asset Turnover | — | 1.04 | 0.86 | 0.82 | 0.67 | 1.24 | 1.23 | 1.31 | 0.87 | 0.50 | 0.68 |
| Inventory Turnover | 3.03 | 3.03 | 2.94 | 3.08 | 3.24 | 4.77 | 4.47 | 2.96 | 3.26 | 3.22 | 4.10 |
| Days Sales Outstanding | — | 96.13 | 171.80 | 70.73 | 69.57 | 54.98 | 80.89 | 66.98 | 33.68 | 59.99 | 58.75 |
SNOA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Sonoma Pharmaceuticals, Inc. returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $909000 | $339400 | $265300 | $199600 | $147700 | $92398 | $50332 | $46932 | $86256 |
Peer Comparison
Compare SNOA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SNOAYou | $2M | -0.4 | — | — | 38.2% | -26.0% | -65.5% | -188.1% | — |
 SSKN | $6M | -0.6 | — | — | 56.9% | -27.6% | -114.2% | -38.9% | — |
 DERM | $104M | -7.0 | — | — | 62.8% | -24.4% | -72.6% | -56.8% | — |
 PRPH | $6M | -0.1 | — | — | -2.2% | -570.6% | -188.1% | -59.4% | — |
 CLSD | $2M | -0.1 | — | — | 91.0% | -1735.7% | — | — | — |
 BRTX | $2M | -0.2 | — | — | 93.0% | -2881.6% | -96.9% | -100.4% | — |
 PAVM | $467M | 14.4 | — | — | -101.6% | -1485.4% | — | -232.4% | — |
 MTNB | $4M | -0.1 | — | — | — | — | -180.7% | -173.9% | — |
 MCK | $90B | 19.2 | 15.3 | 14.7 | 3.6% | 1.5% | 154.5% | 74.5% | 1.4 |
 HSIC | $8B | 21.7 | 10.9 | 14.2 | 29.1% | 5.7% | 8.3% | 7.1% | 3.4 |
 PRGO | $2B | -1.1 | 7.4 | 11.2 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
See SNOA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNOA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNOA vs SSKN
Side-by-side business, growth, and profitability comparison vs STRATA Skin Sciences, Inc..
Start ComparisonSNOA — Frequently Asked Questions
Quick answers to the most common questions about buying SNOA stock.
What is Sonoma Pharmaceuticals, Inc.'s P/E ratio?
Sonoma Pharmaceuticals, Inc.'s current P/E ratio is -0.4x. The historical average is 28.9x.
What is Sonoma Pharmaceuticals, Inc.'s ROE?
Sonoma Pharmaceuticals, Inc.'s return on equity (ROE) is -65.5%. The historical average is -120.9%.
Is SNOA stock overvalued?
Based on historical data, Sonoma Pharmaceuticals, Inc. is trading at a P/E of -0.4x. Compare with industry peers and growth rates for a complete picture.
What are Sonoma Pharmaceuticals, Inc.'s profit margins?
Sonoma Pharmaceuticals, Inc. has 38.2% gross margin and -26.0% operating margin.